Clinical Trials Browser

NCT06770582 2026-03-18

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Phase 2 Recruiting

160 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT07245745 2026-03-16

Prospective Clinical Study Comparing PROMS After Adaptive or Conventional Radiotherapy in Prostate Cancer

Phase NA Recruiting

188 enrolled

Genitourinary

Prostatic Neoplasms

NCT04075305 2026-03-05

MOMENTUM

Recruiting

8,000 enrolled

BreastCNSGastrointestinalGenitourinaryHead & NeckThoracic

Urinary Bladder Neoplasms, Brain Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Genital Neoplasms, Female, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Radiation Injuries, Rectal Neoplasms

Clinical Trials

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Prospective Clinical Study Comparing PROMS After Adaptive or Conventional Radiotherapy in Prostate Cancer

MOMENTUM

Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

METRO

Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT

X-SMILE

Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization

Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial

Pembro With Radiation With or Without Olaparib

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer

Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC

DIVINE

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer

MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)

FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial

APPROACH

A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy

SPRINTR-REAL

FAST-ONE

JUMP

ITALIC-RCC

GrandP/SPCG19

VIRTUAL

Radiotherapy or Surgery Combined With Intense Androgen Deprivation Therapy for mCRPC

Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer

HypoElect

PRIS

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

AMPORA

MEDCARE

SPARKLE

HyBla_RCT

Adjuvant Hypofractionated Radiotherapy for Prostate Cancer

THUNDER

ENFORCE

Neoadjuvant Hormone and Radiation Therapy Followed by Radical Prostatectomy in Patients With High-Risk Prostate Cancer

SPCG-15